Regulation (EU) 745/2017 and market impact: Innate’s excellence in regulatory compliance

In recent years, medical device industry has undergone a profound transformation with the introduction of EU Regulation 2017/745, known as MDR EU 745/2017 (Medical Device Regulation). This new regulatory framework was designed to raise the standards of safety and efficacy of medical products marketed in the European Union, thus ensuring greater protection for patients and stricter transparency throughout the production chain. The MDR has forced companies in the sector to make numerous adjustments and investments in terms of documentation, clinical trials and traceability systems, radically changing the way medical devices are developed, manufactured and marketed.

The move to MDR represents a significant challenge for all companies in the industry of medical device: it involves revising internal processes, updating certifications and adopting new technologies to ensure compliance. However, this regulatory change is not only an obligation, but also offers important opportunities for innovation and market positioning, as companies that can adapt quickly and efficiently to the new regulation can distinguish themselves through quality and reliability.
Moreover, strict regulatory compliance can facilitate access to foreign markets and enhance corporate reputation.

The Impact of MDR on the Medical Device market

The adoption of MDR has inevitably had an impact on the entire medical device market. In particular, companies have to invest considerable resources to update their internal procedures, ensure proper management of clinical data and maintain transparent and constantly updated documentation. This transformation has led to an increased focus on product quality and a reassessment of development processes, with a focus on innovation and sustainability.

The new regulation has also triggered fiercer competition among manufacturers, who must now not only offer high-performance devices, but also ensure complete transparency on the product life cycle. This means that, to be successful, companies must develop a robust compliance management system that integrates technology, research and development and a proactive approach to regulatory communication.

Innate: an example of excellence in MDR compliance

In this context, Innate stands out for its unwavering commitment to quality and innovation. Our company has invested significantly in creating an up-to-date internal regulatory environment that allows us to ensure maximum compliance with ever-changing regulations. We are proud to announce that, in the orthopaedics sector, all our branded products have already made the transition to MDR. We have also achieved this excellent result with our gynaecological products, and soon those in aesthetic medicine will also be covered by the new regulation. This important milestone not only testifies to our ability to adapt quickly to new standards, but also represents added value for our customers, who can count on safe and innovative solutions.

“The Regulation (EU) MDR 745/2017 is a challenge and every challenge is an opportunity to improve ourself”
Dr. Giulia Avio, Regulatory Affairs Manager Innate s.r.l.

We are currently extending this compliance process to the gynaecological sector as well. The goal is to apply the same rigorous regulatory and quality approach to our devices for gynaecological use, so as to ensure safety and efficacy in this sensitive area as well. Our commitment to innovation translates into a constant search for innovative formulations and patented technologies that allow us to offer cutting-edge products in full compliance with European regulations.

The opportunities

The move to MDR, although a complex challenge, opens up new opportunities for Innate. By taking a proactive approach and investing in regulatory compliance, we are able to:

• Strengthen the trust of our customers and patients by ensuring high standards of safety and quality.
• Access international markets with certified and globally recognised products.
• Promote innovation through the development of patented formulations and tailor-made solutions for different industry needs.
• To differentiate ourselves from our competitors by demonstrating a constant commitment to adapting to new regulations and continuously improving our production processes.

Ultimately, MDR is not just a regulation to comply with, but an engine of innovation and growth for the medical device industry. Innate, with its integrated approach and strong focus on quality, is ready to seize these opportunities, offering solutions that combine technological excellence and safety to improve the lives of patients and healthcare professionals.

The path to full MDR compliance requires commitment, resources and a forward-looking vision. Innate has demonstrated its ability to meet this challenge by investing in training its team, updating its processes and finding innovations that can make a difference in the market. With the success achieved in the orthopaedic sector and the extension of the process to the gynaecological field, Innate strengthens its position as a leader in the medical device sector, confirming its commitment to ensuring the highest quality and safety in every product it offers.

The future of the industry is constantly evolving, and we at Innate are ready to lead it, always with transparency, innovation and a keen eye on our customers’ needs.